

DAFTAR PUSTAKA

1. WHO. Global Tuberculosis Report 2016. World Health Organization. 2016: 12.
2. Center for Disease Control and Prevention. Tuberculosis (TB). (updated 2016 March 20; cited 2017 July 20). Available from: <https://www.cdc.gov/tb/default.htm>
3. Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2016.2016: 178-79.
4. Perhimpunan Dokter Paru Indonesia. Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. 2006: 1-20.
5. Istiantoro Y, Setiabudy R. Tuberkulostatik dan leprostatik. In: Sulistia, Gunawan, Setiabudy R, Nafrialdi, editors. Farmakologi dan Terapi. 5th ed. Jakarta: Balai Penerbit FK UI; 2012;5:613-19.
6. Bahar A, Amin Z. Tuberkulosis paru. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam Jilid 1. 6th ed. Jakarta: Interna Publishing; 2014;6:863-73.
7. Gulbay B, Gurkan O, Yildiz O, Onen Z, Erkekol F. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Elsevier. 2006;100:1834-42.
8. Arbex M, Varella M, Siqueira H, Mello F. Antituberculosis drugs : drug interactions, adverse effects, and use in special situations. Scielo Analytics. 2010;36(5): 2.
9. Alwi, Nurazminah. Prevalensi pasien TB paru yang mengalami hepatitis imbas OAT dan faktor resiko yang berhubungan di RSPU Persahabatan Jakarta dan RSPG Cisarua pada tahun 2012. Unisba. 2013:41-48.
10. World Health Organization. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the iuat trial. Bull World Health Organ. 1982;60(4):555-64.
11. American Thoracic Society. Diagnostic standard and classification of tuberculosis in adults and children. American Journal of Respiratory and Critical Care Medicine. 1999;161:1376-92.
12. Raviglione MC. Tuberculosis. In: Kasper D, Pauci A, Hauser S, Longo D, Jameson L, Loscalzo J, editors. Harrison's principles of internal medicine 19th ed. United States of America: Mc Graw-Hill Education/Medical; 2015;19:1103-15

13. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. *World J Gastroenterol*. 2008;14(44):6774-85.
14. Hayashi P, Fontana R, Chalasani N, Stolz A, Talwalker J, Navarro V et al. Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. *Clin Gastroenterol Hepatol*. 2015;13(9):1676-82.
15. Hassan H, Guo H, Yousef B, Luyong Z, Zhenzhou J. Hepatotoxicity of isoniazid: a mini review. *Journal of Applied Toxicology*. 2015;35(12):1427-32.
16. Metushi I, Utrecht J, Philips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. *Br J Clin Pharmacol*. 2016;81(6):1030-36.
17. Khayyam K, Imam F, Sharma M, Pillai K, Behera D. Pyrazinamide-Induced Maculopapular Rash. *Br J Clin Pharmacol*. 2016;81(6):1030-36.
18. Gaude GS, Chaudury A, Hattiholi J. Drug induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. *J Family Med Prim Care*. 2015;4(2):238-43.
19. Shih T, Yi Pai C, Yang P, Liang Chong W, Wang N. A Novel Mechanism Underlines the Hepatotoxicity of Pyrazinamide. *Antimicrobs Agents Chemother*. 2013;57(4):1685-90.
20. Guo YX, Xu XF, Zhang QZ, Li C, Deng Y, Jiang P et al. The inhibition of hepatic bile acids transporter Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity. *Toxicol Mech Methods*. 2015;25(5):382-7.
21. Kim JH, Nam WS, Kim SJ, Kwon OK, Seung EJ, Jo JJ et al. Mechanism investigation of rifampicin-induced liver injury using comparative toxicoproteomics in mice. *Int J Mol Sci*. 2017;18(7):7-8.
22. Ramappa V, Aithal G. Hepatotoxicity Related to Anti-Tuberculosis Drugs: Mechanism and Management. *J Clin Exp Hepatol*. 2013;3(1):37-49.
23. Pandit S, Choudhury S, Das A, Datta S, Das S. Isoniazid-Induced Flu Like Syndrome : A Rare Side Effect. *Lung India*. 2013;30(1):61-63.
24. Koul, Parvaiz A. Ocular Toxicity With Ethambutol Therapy: Timely Recaution. *Lung India*. 2015;32(1):1-3.

25. Vasantha M, Gopi PG, Subramani R. Weight Gain In Patients With Tuberculosis Treated Under Directly Observed Treatment Short Course (DOTS). *Indian J Tuberc.* 2009;56(1);5-9.
26. Phan M, Guy E, Nickson R, Kao C. Predictors and patterns of weight gain during treatment for tuberculosis in the United States of America. Elsevier. 2016:1-4.
27. Gler M, Guilatco R, Caoili J, Ershova J, Cegielski P, Johnson J. Weight Gain and Response to Treatment for Multidrug-Resistant Tuberculosis. *Am J Trop Med Hyg.* 2013;89(5):943-49.
28. Jeong I, Park J, Lee J. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. *J Korean Med Sci.* 2015;30(2):167-72.
29. Chiang C, Yu M, Shih H, Yen M, Hsu Y. Improved Consistency in Dosing Anti-Tuberculosis Drugs in Taipei, Taiwan. *Plos One.* 2012;7(9):1-3.